{'fraction_non_alphanumeric': 0.024965325936199722, 'fraction_numerical': 0.030513176144244106, 'mean_word_length': 4.966942148760331, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 3, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Impact of Sirolimus Duration on Hepatitis C Related Fibrosis Progression in Liver Transplant Recipients

However, upon close examination of the subgroup analyses, the correlation may not be as strong as it is stated. Specifically, data for patients remaining on sirolimus for the longest duration (>300 days and >700 days) is included in all subgroups. Including the data for those on sirolimus for the longest duration in multiple groups makes the effect of sirolimus on fibrosis appear more pronounced than it is. In order to address whether the effect of sirolimus depends on its duration, a more appropriate illustration would be to present the data as sirolimus use ≤90 days, 91–300 days, 301–700 days and >700 days.